Trust Signals
Evidence standard: Claims graded by evidence type below. Speculative claims are labeled. No affiliate relationships influence content.
Regulatory status: Kisspeptin-10 is not FDA-approved. This page is for educational and research literacy purposes only.
Key Takeaways
- Published human clinical trials at Imperial College London used IV kisspeptin-10 doses of 0.1 to 10 nmol/kg, with 1 nmol/kg IV producing consistent LH pulses in healthy men.
- Kisspeptin-10 has a plasma half-life estimated at under 4 minutes IV; continuous dosing causes receptor desensitization and paradoxically suppresses LH.
- Pulsatile dosing every 90 to 120 minutes is required to preserve KISS1R sensitivity and sustain gonadotropin output.
- Bodybuilding doses of 50 to 100 mcg SC circulating online are entirely empirical; no controlled trial has validated them for post-cycle recovery or hypertrophy.
- A legitimate COA for research-grade kisspeptin-10 must confirm the C-terminal amide group (YNWNSFGLRF-amide), mass spec MW near 1302 Da, and endotoxin below 1 EU/mg.
Direct Answer: What Is the Kisspeptin-10 Dosage Schedule?
In human research, the most-used kisspeptin-10 dosage is 1 nmol/kg given as an intravenous bolus, producing a single robust LH pulse lasting roughly 60 minutes. Sustained stimulation requires pulsatile injections every 90 to 120 minutes. No FDA-approved dosing protocol exists. Subcutaneous research doses are higher, roughly 3 to 5 times the IV dose, to compensate for reduced bioavailability.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How does kisspeptin-10 actually stimulate testosterone?
- What doses were used in human clinical trials?
- What is the kisspeptin-10 dosage for men specifically?
- What does the bodybuilding dosage evidence actually look like?
- Evidence ledger: graded claims table
- What most pages get wrong about kisspeptin-10 dosing
- Why continuous dosing fails: the receptor chemistry
- Head-to-head: kisspeptin-10 vs GnRH vs hCG
- Operational guide: COA reading, reconstitution, dosing math
- FAQ
- Sources
How Does Kisspeptin-10 Actually Stimulate Testosterone?
Kisspeptin-10 is the C-terminal decapeptide fragment (residues 45 to 54 in some numbering schemes, depending on species) of the KISS1 gene product. Its sequence in humans is YNWNSFGLRF-amide, and the C-terminal amide group is required for full receptor affinity. It binds KISS1R (also called GPR54), a Gq/11-coupled GPCR expressed predominantly on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei.
KISS1R activation triggers intracellular IP3/DAG signaling, depolarizing GnRH neurons and driving pulsatile GnRH release into the hypophyseal portal blood. GnRH then binds pituitary GnRH receptors, releasing LH and FSH. LH acts on testicular Leydig cells to produce testosterone. The full signal cascade from kisspeptin injection to detectable LH rise occurs within 5 to 15 minutes of IV bolus in published human studies.
What this mechanism does NOT prove: upstream KISS1R activation does not guarantee downstream testosterone normalization in men with testicular failure, pituitary adenoma, or severe GnRH neuron loss (Kallmann syndrome). The cascade must be intact at every step.
What Doses Were Used in Human Clinical Trials?
The most rigorous published human data comes from the Dhillo group at Imperial College London. Key dose points:
| Study Context | Route | Dose Range | LH Response | Notes |
|---|---|---|---|---|
| Healthy men, dose-finding (Dhillo et al., 2005, Journal of Clinical Endocrinology and Metabolism) | IV bolus | 0.1, 0.3, 1.0 nmol/kg | Dose-dependent LH rise; robust at 1 nmol/kg | n=6 per dose group; single-center |
| Hypogonadotropic hypogonadism diagnostic (Chan et al., 2009, JCEM) | IV bolus | 1 nmol/kg | LH rise distinguishes FHH from Kallmann | Diagnostic utility confirmed |
| Pulsatile infusion, healthy men (George et al., 2011, JCEM) | SC infusion pump | 4 nmol/kg per pulse, every 90 min | Sustained LH pulsatility over 22 hours | n=6; first pulsatile SC protocol in men |
| Higher IV dose exploration | IV bolus | Up to 10 nmol/kg | Larger LH pulse amplitude, no serious AEs | Well tolerated in published Phase I data |
Important caveat: All of these are small trials (typically n=6 to 20) designed to characterize pharmacodynamics, not to establish therapeutic efficacy for any clinical indication. Effect sizes are pharmacological endpoints (LH amplitude), not clinical outcomes (fertility, testosterone normalization at 3 months).
What Is the Kisspeptin-10 Dosage for Men Specifically?
For research involving adult men, the dosing parameters with the most published support are:
- Single IV bolus: 1 nmol/kg body weight (approximately 70 to 90 nmol for a 70 to 90 kg man), producing one discrete LH pulse.
- Pulsatile SC protocol: approximately 4 nmol/kg per pulse administered every 90 to 120 minutes via infusion pump, replicating the natural GnRH pulse frequency.
- Duration: published pulsatile trials ran for single 22-hour sessions or short multi-day periods. No long-term (weeks to months) male dosing RCT exists as of this writing.
Converting nmol/kg to micrograms: kisspeptin-10 molecular weight is approximately 1302 Da. At 1 nmol/kg for a 75 kg man: 75 nmol x 1302 g/mol = roughly 97.6 mcg IV. At 4 nmol/kg SC per pulse: approximately 390 mcg per SC pulse. These figures give context for evaluating the plausibility of community-derived doses.
What Does the Bodybuilding Dosage Evidence Actually Look Like?
Community protocols typically cite 50 to 100 mcg subcutaneous, once or twice daily, often framed as post-cycle therapy to restore the HPG axis after anabolic steroid suppression. The theoretical rationale is that stimulating KISS1R will restart endogenous GnRH pulsatility suppressed by exogenous androgens.
Problems with this framing:
- Post-steroid HPG suppression primarily involves elevated estradiol and androgen feedback suppressing kisspeptin neurons. Adding exogenous kisspeptin-10 may stimulate a pathway that feedback is already blocking.
- 50 to 100 mcg SC is roughly 38 to 77 nmol for a 75 kg person, which falls in the range of a single 0.5 to 1 nmol/kg IV dose equivalent on paper, but SC bioavailability, injection-site degradation, and the absence of a pump mean the kinetics are entirely different.
- No randomized trial, case series with matched controls, or even a well-documented case report has evaluated kisspeptin-10 for post-cycle restoration of testosterone. This is a gap, not a body of evidence.
- The very short half-life (under 4 minutes IV) means a once-daily SC injection produces a transient stimulus followed by a long period of no KISS1R activation. Whether this pulse pattern is beneficial, neutral, or desensitizing at community doses is unknown.
Evidence Ledger: Graded Claims Table
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| IV kisspeptin-10 at 1 nmol/kg produces LH pulse in healthy men | Human RCT/controlled trial (Dhillo et al., 2005; multiple replications) | Positive | High |
| Continuous infusion causes LH suppression via desensitization | Human controlled infusion studies (George et al.) | Negative (suppressive) | High |
| Pulsatile SC dosing sustains LH pulsatility over hours in men | Small human controlled trials (George et al., 2011) | Positive | Moderate |
| Kisspeptin-10 useful to distinguish FHH from Kallmann syndrome | Human clinical studies, replicated | Positive (diagnostic) | Moderate |
| SC dose needs to be 3-5x higher than IV for equivalent LH response | Indirect extrapolation from pharmacodynamic data; no direct head-to-head bioavailability RCT | Probable | Low |
| 50-100 mcg SC daily restores testosterone after steroid suppression | No controlled human data; forum reports only | Unknown | Very Low |
| Kisspeptin-10 is safe at up to 10 nmol/kg IV in healthy adults | Phase I human data | Positive (tolerability) | Moderate |
| Kisspeptin-10 improves fertility outcomes in hypogonadotropic men | Early-phase human trials; small samples, no Phase III | Preliminary positive | Low |
What Most Pages Get Wrong About Kisspeptin-10 Dosing
Nearly every competing article converts trial doses to a flat microgram figure without weight-adjusting, stripping the nmol/kg structure entirely. This is scientifically illiterate. A 1 nmol/kg IV dose is roughly 98 mcg for a 75 kg person and roughly 118 mcg for a 90 kg person. Presenting a single flat dose ignores a roughly 20% variance just across normal body weight ranges, before bioavailability differences are considered.
The formulation gotcha most pages ignore: kisspeptin-10 requires a C-terminal amide (YNWNSFGLRF-amide) for full KISS1R binding. The non-amidated form (with a free carboxyl group) has substantially reduced receptor affinity in in vitro assays. Many research peptide vendors sell kisspeptin-10 without specifying amidation status on their storefront. A COA that shows the correct molecular weight (~1302 Da) for the amidated form, confirmed by mass spectrometry, is the only way to verify this. A free-acid form would show ~1303 Da (one mass unit higher) and would likely be less potent. This single point is absent from essentially every consumer-facing kisspeptin article.
Penetration and bioavailability reality: SC bioavailability for small peptides is highly variable and affected by injection technique, adipose thickness, tissue perfusion, and local peptidase activity. No published kisspeptin-10 SC absolute bioavailability study in humans has produced a definitive percentage. Citing a precise number here would be fabrication.
Why Continuous Dosing Fails: The Receptor Chemistry
KISS1R is a Gq/11-coupled GPCR. Like all GPCRs, it undergoes agonist-induced internalization via beta-arrestin recruitment and receptor endocytosis when continuously occupied. Sustained KISS1R activation leads to receptor phosphorylation (by GRK2 and GRK3 kinases), beta-arrestin binding, and clathrin-mediated endocytosis, reducing surface receptor density. This is the same mechanism by which continuous GnRH agonists (like leuprolide acetate) paradoxically suppress testosterone after an initial flare.
The 90 to 120 minute pulsatile interval used in clinical research is not arbitrary. It matches the approximate period of natural GnRH pulsatility in men, allowing receptor recycling back to the cell surface between pulses. If you dose more frequently than receptor recycling allows, you recreate the continuous-agonist suppression phenotype. If you dose far less frequently, you simply generate isolated, non-sustained LH pulses without maintaining downstream testosterone production.
This explains why once-daily SC injections as promoted in bodybuilding communities are almost certainly producing a single transient LH pulse followed by 23+ hours of no stimulation, not a sustained physiological restoration of pulsatile GnRH signaling. Whether that single daily pulse is clinically meaningful is an open empirical question with no current answer.
Head-to-Head: Kisspeptin-10 vs. GnRH vs. hCG
| Feature | Kisspeptin-10 | GnRH (Gonadorelin) | hCG |
|---|---|---|---|
| Target | KISS1R on GnRH neurons (hypothalamus) | GnRH receptor on pituitary gonadotrophs | LH receptor on testicular Leydig cells |
| Half-life (IV) | Under 4 minutes (estimated) | Approximately 2-4 minutes | Approximately 24-36 hours (beta subunit) |
| FDA-approved formulations | None | Yes (gonadorelin, factrel; limited use) | Yes (multiple brands) |
| Requires pulsatile dosing | Yes, critical | Yes, for stimulation; continuous suppresses | No; long half-life provides sustained signal |
| Preserves FSH stimulation | Yes (via GnRH) | Yes | No (LH receptor only; no FSH) |
| Useful if pituitary is damaged | No | No | Yes |
| Evidence for male hypogonadism | Phase I/II, small n | Limited, mostly fertility | Extensive RCT data |
| Where kisspeptin-10 loses | Half-life, delivery complexity, no approval, cost | Slightly easier delivery than kisspeptin-10 | Kisspeptin-10 wins on physiological fidelity; hCG wins on evidence and convenience |
Honest conclusion: for most practical purposes where the goal is raising testosterone, hCG has far more clinical evidence and a manageable dosing schedule. Kisspeptin-10 is scientifically interesting as a tool for studying the HPG axis and potentially for cases where naturalizing the full pulsatile axis matters (e.g., fertility preservation), but it is not a superior practical alternative to approved agents at this stage of evidence.
Operational Guide: COA Reading, Reconstitution, and Dosing Math
Reading a COA for Kisspeptin-10
Demand all of the following from any research supplier:
- Sequence confirmation: YNWNSFGLRF-amide (the amide notation is critical, see above)
- Molecular weight by MS: approximately 1302.5 Da for the amide form. If the vendor shows ~1303.5 Da (free acid) or does not include MS data, reject the lot.
- HPLC purity: 98% or above for research use
- Endotoxin: below 1 EU/mg (LAL assay). No endotoxin testing = not suitable for injection research
- Moisture/TFA content: lyophilized peptides often retain trifluoroacetic acid from synthesis; TFA should be reported and ideally exchanged for acetate to reduce counterion toxicity
Reconstitution
Use bacteriostatic water (0.9% benzyl alcohol) for multi-use vials, or sterile water for single-use. Do not inject forcefully into the lyophilate cake; swirl gently. A common reconstitution for a 1 mg vial: add 1 mL bacteriostatic water to yield 1000 mcg/mL (1 mcg/uL). For a 75 kg subject at a research dose of 1 nmol/kg IV (~98 mcg), you would draw approximately 0.1 mL (100 uL) from this solution.
Stability After Reconstitution
The tryptophan (W) and methionine-free but oxidation-sensitive aromatic residues in kisspeptin-10 make it susceptible to oxidative degradation under light and at elevated temperatures. Reconstituted solution should be stored at 4 degrees Celsius, protected from light, and used within a few days. Visible cloudiness or discoloration indicates degradation; discard the vial. Repeated freeze-thaw cycles of reconstituted peptide accelerate peptide bond hydrolysis and should be avoided.
Dosing Calculation Reference Table
| Body Weight | 1 nmol/kg IV | 4 nmol/kg SC (per pulse) | Volume from 1 mg/mL solution |
|---|---|---|---|
| 60 kg | ~78 mcg | ~312 mcg | 0.078 mL / 0.31 mL |
| 75 kg | ~98 mcg | ~391 mcg | 0.098 mL / 0.39 mL |
| 90 kg | ~117 mcg | ~469 mcg | 0.117 mL / 0.47 mL |
| 100 kg | ~130 mcg | ~521 mcg | 0.130 mL / 0.52 mL |
These figures use kisspeptin-10 MW of approximately 1302 Da. They are reference calculations for research context only.
Frequently Asked Questions
What is the standard kisspeptin-10 dosage used in clinical research?
Human clinical trials have used intravenous doses ranging from 0.1 to 10 nanomoles per kilogram (nmol/kg), with the 1 nmol/kg IV dose consistently producing robust LH pulses in healthy men in studies from the Imperial College London group. Subcutaneous doses in research are typically higher to account for reduced bioavailability.
What is the kisspeptin-10 dosage schedule for men in clinical trials?
Published trials most commonly used single IV bolus doses of 1 to 4 nmol/kg or pulsatile subcutaneous infusions every 90 to 120 minutes. Daily continuous infusion causes receptor desensitization and suppresses LH output.
Can kisspeptin-10 be dosed subcutaneously, and does the dose change?
Yes. Subcutaneous bioavailability is lower than IV. Research groups have used roughly 3 to 5 times higher subcutaneous doses to achieve comparable LH responses. No head-to-head SC vs IV bioavailability RCT in humans has been published with a definitive ratio.
What kisspeptin-10 bodybuilding dosage is circulating online, and is it evidence-based?
Bodybuilding forums cite 50 to 100 mcg subcutaneous doses, typically post-cycle to stimulate LH. These doses are empirical, not drawn from controlled trials, and no RCT has evaluated kisspeptin-10 for post-cycle testosterone restoration. The theoretical rationale involves KISS1R activation of GnRH neurons, but efficacy and safety in this context are unproven.
How long does kisspeptin-10 stay active after injection?
Kisspeptin-10 has a very short plasma half-life, estimated at under 4 minutes for IV administration in humans based on the rapid LH pulse decay seen after bolus injection in clinical studies. This rapid clearance is why pulsatile, not continuous, dosing is required for sustained gonadotropin stimulation.
What happens if kisspeptin-10 is dosed continuously rather than in pulses?
Continuous kisspeptin-10 infusion causes KISS1R desensitization and paradoxical LH suppression, mirroring the tachyphylaxis seen with GnRH agonist continuous dosing. The Dhillo group at Imperial College London documented this effect. Pulsatile dosing every 90 to 120 minutes preserves receptor sensitivity.
Is kisspeptin-10 FDA-approved, and can it be prescribed?
No kisspeptin formulation is FDA-approved as of the date of this publication. It is an investigational research peptide. Off-label or self-administration outside a supervised research protocol is not endorsed by any regulatory body.
How should kisspeptin-10 be reconstituted and stored?
Research-grade kisspeptin-10 lyophilate should be reconstituted with bacteriostatic water or sterile saline. Store the lyophilate at -20 degrees Celsius before reconstitution. Once reconstituted, keep at 4 degrees Celsius and use within a few days. Methionine-adjacent aromatic residues are oxidation-sensitive, so avoid prolonged room-temperature exposure.
What are the documented side effects of kisspeptin-10 at clinical doses?
Published human trials report kisspeptin-10 is well tolerated at doses up to 10 nmol/kg IV. Transient LH and testosterone surges are pharmacological effects, not adverse events. Mild injection-site reactions occur with SC administration. No serious adverse events attributable to kisspeptin-10 were reported in published Phase I/II studies from the Imperial College group.
How does kisspeptin-10 compare to GnRH or hCG for stimulating testosterone?
GnRH (gonadorelin) acts one step downstream of kisspeptin at GnRH receptors on pituitary cells. hCG acts directly on testicular LH receptors, bypassing the HPG axis entirely. Kisspeptin-10 acts furthest upstream and has the shortest half-life, making sustained effects hardest to achieve without pulsatile delivery. hCG has the largest clinical evidence base.
Does kisspeptin-10 work differently in men with hypogonadotropic hypogonadism?
Men with functional hypogonadotropic hypogonadism (FHH) retain KISS1R-responsive GnRH neurons and show LH responses to kisspeptin-10, which has been used to distinguish FHH from Kallmann syndrome in diagnostic research. Men with true Kallmann syndrome (absent GnRH neurons) have an absent or blunted response.
What should a COA for research-grade kisspeptin-10 show?
A credible COA should confirm: amino acid sequence matching human kisspeptin-10 (YNWNSFGLRF-amide), purity at or above 98% by HPLC, mass spectrometry confirmation of molecular weight (approximately 1302 Da for the amide form), endotoxin testing below 1 EU/mg, and moisture content. Absence of MS data or endotoxin testing is a red flag.
Sources
- Dhillo WS, Chaudhri OB, Patterson M, et al. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." Journal of Clinical Endocrinology and Metabolism. 2005;90(12):6609-6615.
- George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. "Exploring the pathophysiology of hypogonadotropic hypogonadism in men: pulsatile GnRH secretion is impaired above the level of the GnRH pulse generator." Journal of Clinical Endocrinology and Metabolism. 2011;96(7):E1097-E1101.
- Chan YM, Butler JP, Pinnell NE, et al. "Kisspeptin resets the hypothalamic GnRH clock in men." Journal of Clinical Endocrinology and Metabolism. 2011;96(6):E908-E915.
- Dhillo WS, Chaudhri OB, Thompson EL, et al. "Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women." Journal of Clinical Endocrinology and Metabolism. 2007;92(10):3958-3966.
- Seminara SB, Messager S, Chatzidaki EE, et al. "The GPR54 gene as a regulator of puberty." New England Journal of Medicine. 2003;349(17):1614-1627.
- Clarkson J, d'Anglemont de Tassigny X, Moreno AS, Colledge WH, Herbison AE. "Kisspeptin-GPR54 signaling is essential for preovulatory gonadotropin-releasing hormone neuron activation and the luteinizing hormone surge." Journal of Neuroscience. 2008;28(35):8691-8697.
- Jayasena CN, Abbara A, Veldhuis JD, et al. "Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54." Journal of Clinical Endocrinology and Metabolism. 2014;99(6):E953-E961.
- Ramaswamy S, Seminara SB, Plant TM. "Evidence from the agonadal juvenile male rhesus monkey (Macaca mulatta) for the view that the action of kisspeptin on the gonadotropin-releasing hormone pulse generator is gated by maturation of the hypothalamic network." Neuroendocrinology. 2011;93(3):199-210.
Footer Disclaimers
Platform: This page is published by FormBlends for educational and research literacy purposes. It does not constitute medical advice, diagnosis, or treatment recommendation. Consult a licensed physician before using any peptide or hormone-related compound.
Research Compound: Kisspeptin-10 is not approved by the FDA or any equivalent regulatory agency for therapeutic use in humans as of the date of publication. It is classified as an investigational research compound. References to dosing are drawn from published clinical research and are provided to support scientific literacy, not to guide self-administration.
Results: Individual responses to peptides vary substantially based on physiology, health status, and route of administration. No outcome described on this page is guaranteed. Effect sizes cited are from controlled research settings and may not replicate outside those conditions.
Trademark: All product names, brand names, and trademarks mentioned on this page are the property of their respective owners. FormBlends is not affiliated with Imperial College London or any clinical research institution
Related peptide guides
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Kisspeptin-10 Dosage Schedule: Evidence-Based Guide | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Kisspeptin-10 Dosage Schedule: Evidence-Based Guide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Kisspeptin
Kisspeptin now carries extra 2026 context around testosterone, cash-pay pricing, safety signals, peptides, kisspeptin, dosage, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.
Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to peptides kisspeptin dosage.
Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.
Custom 2026 image for Kisspeptin, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Medical Content Team
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.